Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

SSavara Inc

EconomyAI buildoutMarket MapFundsWatchlist
Log in
S

Savara Inc

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
    Aug 24, 2026Savara Inc. Press Releases
  • Savara Announces New Employment Inducement Grant
    Aug 20, 2026Savara Inc. Press Releases
  • Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
    Aug 11, 2026Savara Inc. Press Releases
  • Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
    Jul 30, 2026Savara Inc. Press Releases
  • Savara Announces New Employment Inducement Grant
    Jun 12, 2026Savara Inc. Press Releases
  • Savara Announces Chief Financial and Administrative Officer Transition
    Jun 8, 2026Savara Inc. Press Releases
  • Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
    May 27, 2026Savara Inc. Press Releases
  • Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026
    May 20, 2026Savara Inc. Press Releases
  • Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    May 19, 2026Savara Inc. Press Releases
  • Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
    May 18, 2026Savara Inc. Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions